This Event Ran on March 2022

7:30 am Registration & Networking

Examining Inflammatory Interstitial Lung Disease from a Drug Development Perspective

8:25 am Chair’s Opening Remarks

• Meera Ramanujam Executive Director, Immunology and Translational Research, Aro Biotherapeutics

8:30 am Comparing & Contrasting Fibrotic & Inflammatory ILDs in Order to Comprehensively Understand Key Differences in Their Development & Progression & Learning How This Influences Drug Development

• Stephen Christensen Translational Systems Biologist-Immunologist , Pfizer

9:00 am Minding the Gap: SES in ILD Care & Trials

• Nina Patel Director – Clinical Development & Medical Affairs ILD, Boehringer Ingelheim

9:30 am Designing Trials for Inflammatory ILDs in 2022 & Beyond: Spotlight on Ssc-ILD

• Dinesh Khanna Professor, University of Michigan

10:00 am Speed Networking

10:30 am Morning Break

Biomarkers 101: Exploring the Emerging Consensus on Which Biomarker is the Most Useful for ILD Drug Development

11:00 am OSIC Project – Exploring Imaging Based Biomarkers, CT Scans/ Data Collection to Predict FVC Decline

• David Barber Professor of Machine Learning , UCL

11:30 am Exploring Biomarkers for Differential Diagnosis of Interstitial Lung Diseases

• Paolo Cameli Pulmonologist, University of Siena

12:00 pm Lunch & Networking

Revealing Supportive Care & Symptom Management for ILD Treatment

1:00 pm Exploring the Impact & Importance of Quality of Life on the Patient Journey

• Farrell Simon Vice President & Head of US Marketing, Trevi Therapeutics

Exploring Endpoints for Clinical Trials

1:30 pm Driving Efficiencies in ILD drug Trials Through Lung Intelligence: How Precision Imaging Biomarkers & an AI-Driven Cloud Platform are Helping Accelerate New Therapies to Patients

• Susan Wood Chief Executive Officer , Vida Lung

1:45 pm Devising & Developing Composite Endpoints Which are Realistic & Achievable to Use in Your Next Clinical Trial

• Peter Fernandes Vice President & Chief Regulatory, Quality & Safety Officer, Bellerophon Therapeutics

2:15 pm Exploring Endpoints in the Context of Inflammatory ILDs: Debating Which Factors You Must Measure to Accurately Assess the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs

• Elizabeth Renzoni Consultant Respiratory Physician, Honorary Senior Lecturer, Imperial College London

2:45 pm Afternoon Break & Networking

Innovative Imaging for Interstitial Lung Disease

3:00 pm Machine Learning & Interstitial Lung Disease: A Deep Dive

• Simon Walsh Consultant Thoracic Radiologist, Machine Learning Scientist & Imaging Chair, Imperial College London

3:30 pm Investigating Imaging Technologies in Lung Fibrosis Drug Discovery

• Fabio Stellari Molecular Imaging Facility-Experimental Pharmacology & Translational Science Senior Scientist, Chiesi Pharmaceuticals

4:00 pm Chair’s Closing Remarks